The 2023 Guidance recommends that, upon receiving an order for synthetic nucleic acids, providers and third-party vendors perform sequence screening, verify the identity of their customers, and follow up to verify the legitimacy of the order when sequences in the Guidance's category of concern are identified.
One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.
What it connects
Screening Framework Guidance for Providers and Users of Synthetic Nucleic Acids → states provision → Recommended provider actions on receiving an order: sequence screening, customer identity verification and follow-up
Where it appears
No collection page holds this claim. It is listed with its records in the explorer.